Home » Stocks » X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (XFOR)

Stock Price: $8.97 USD -0.14 (-1.54%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 144.80M
Revenue (ttm) 3.00M
Net Income (ttm) -53.07M
Shares Out 16.14M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $8.97
Previous Close $9.11
Change ($) -0.14
Change (%) -1.54%
Day's Open 9.26
Day's Range 8.79 - 9.26
Day's Volume 34,808
52-Week Range 5.84 - 15.95

More Stats

Market Cap 144.80M
Enterprise Value 57.61M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 16.14M
Float 10.52M
EPS (basic) -3.12
EPS (diluted) -3.30
FCF / Share -2.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 158,763
Short Ratio 1.86
Short % of Float 1.00%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 48.27
PB Ratio 1.32
Revenue 3.00M
Operating Income -51.85M
Net Income -53.07M
Free Cash Flow -52.56M
Net Cash 87.19M
Net Cash / Share 5.40
Gross Margin n/a
Operating Margin -1,728.20%
Profit Margin -1,769.10%
FCF Margin -1,752.03%
ROA -27.13%
ROE -71.61%
ROIC -214.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$20.00*
(122.97% upside)
Low
14.0
Current: 8.97
High
25.0
Target: 20.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-51.70-29.09-22.25-24.35-14.83
Net Income-52.81-33.29-21.99-22.98-13.22
Shares Outstanding11.530.460.460.090.08
Earnings Per Share-4.63-79.15-54.58-268.74-156.12
Operating Cash Flow-48.06-25.42-21.31-21.64-10.82
Capital Expenditures-0.17--0.38-0.07-0.17
Free Cash Flow-48.23-25.42-21.69-21.71-10.99
Cash & Equivalents1268.1377.153.437.10
Total Debt22.919.8312.2415.297.19
Net Cash / Debt103-1.7064.91-11.86-0.10
Assets1619.9481.257.609.51
Liabilities31.4821.6222.5524.3313.88
Book Value129-77.0958.71-56.56-34.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name X4 Pharmaceuticals, Inc.
Country United States
Employees 63
CEO Paula S. Ragan

Stock Information

Ticker Symbol XFOR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XFOR

Description

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.